Enanta Pharmaceuticals Inc's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Enanta Pharmaceuticals Inc's ROA in the third quarter of 2026?
Enanta Pharmaceuticals Inc recorded a cumulative net loss of $-63 million during 12 months ending in the third quarter of 2026, resulting in a negative return on assets (ROA) of -21.56%.

However, within the Healthcare sector 371 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3480, from total ROA ranking in the second quarter of 2026 at 4152.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) III. Quarter	(Mar 31 2026) II. Quarter	(Dec 31 2025) I. Quarter	(Sep 30 2025) IV. Quarter	(Jun 30 2025) III. Quarter
Y / Y Total Assets Change	-1.38 %	-2.57 %	-25.47 %	-25.47 %	-31.79 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-63	-62	-72	-82	-92
Return On Assets (TTM)	-21.56 %	-21.06 %	-24.14 %	-25.56 %	-26.72 %
ENTA's Total Ranking	# 3480	# 4152	# 3667	# 3721	# 3770
Total Assets (TTM) in million	297	315	281	281	301
Seq. Total Assets Change	-5.67 %	12.1 %	0 %	-6.74 %	-6.8 %
Seq. Net Income Change	-	-	-	-	-

ENTA's 5 Years Annual ROA >> Back to ENTA Management Effectiveness >> Compare ENTA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 135
Sector	# 372
Overall	# 3462

Return On Assets Statistics
High	Average	Low
64.66 %	-3.72 %	-34.1 %
(Mar 31 2015)		(Mar 31 2023)

News about Enanta Pharmaceuticals Inc Return on Assets ROA

Enanta Pharmaceuticals Navigating Challenges and Opportunities in the Virology Landscape

: Enanta Pharmaceuticals, Inc. recently reported its financial results for the fiscal year ending September 30, 2024. The clinical-stage biotechnology firm, known for its focus on developing small molecule drugs for virology and immunology indications, saw a notable decline in revenue despite encouraging data from its Phase 2a human challenge study of EDP-323, an RSV L-inhibitor. This article examines the company’s financial performance in the context of the competitive landscape and highlights key data that could shape its future. As a clinical-stage biotechnology company, Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) is dedicated to advancing therapies for viral and immunological diseases. Recent reporting of financial outcomes for the fiscal fourth quarter and the year ended September 30, 2024, presents an important perspective on both the company s trajectory and the broader implications within the pharmaceutical sector.

Financial Statements
Enanta Pharmaceuticals Inc's Assets	$ 297 million	ENTA's Balance sheet
Enanta Pharmaceuticals Inc's Income	$ -20 million	Quarterly ENTA's Income Statement
ENTA's Income by Division		See ENTA's Income by Division

Annual Return On Assets	(Sep 30 2025) FY 2025	(Sep 30 2024) FY 2024	(Sep 30 2023) FY 2023	(Sep 30 2022) FY 2022	(Sep 30 2021) FY 2021
Y / Y Total Assets Change	-35.29 %	-14.92 %	25.45 %	-18.87 %	-9.51 %
Total Assets in million	244	377	443	353	435
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-82	-116	-134	-122	-79
Annual Return On Assets	-33.6 %	-30.81 %	-30.23 %	-34.5 %	-18.16 %

ENTA's 5 Years Annual ROA >> Back to ENTA Management Effectiveness >> Compare ENTA ROA to its Competitors

More Return On Assets Ratios
ENTA's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ENTA's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ENTA's Competitors
Subscribers only: Roa for Enanta Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Assets for ENTA's Customers

You may also want to know
ENTA's Roi	ENTA's Inventory Turnover Ratio	ENTA's Growth Rates	ENTA's Dividend Comparisons
	ENTA's Profitability Ratios	ENTA's Asset Turnover Ratio	ENTA's Dividend Growth
ENTA's Roe	ENTA's Valuation Ratios	ENTA's Financial Strength Ratios	ENTA's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T06:55:41+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.